Agilisium, a leading data and AI solutions provider, has announced a significant investment to accelerate AI adoption and transformation across pharma, biotech, and medtech companies. The initiative focuses on building specialized AI platforms, generative AI tools, and data-driven solutions that streamline R&D, clinical trials, manufacturing, supply chain, and commercial operations while addressing regulatory compliance and cost pressures in the life sciences sector.
Glimpse:
Agilisium’s investment will fuel development of industry-specific AI accelerators, including generative AI for drug discovery insights, predictive analytics for clinical trial optimization, real-time manufacturing monitoring, and personalized commercial strategies. The company aims to partner with 50+ pharma, biotech, and medtech clients over the next 3 years, delivering measurable ROI through faster time-to-market, reduced R&D costs, improved trial success rates, and enhanced regulatory reporting, leveraging its deep expertise in cloud, data engineering, and AI.
Agilisium, a fast-growing data and AI services company with a strong footprint in life sciences, has unveiled a major strategic investment to transform how pharmaceutical, biotechnology, and medical technology companies harness artificial intelligence. The announcement, made on February 27, 2026, reflects Agilisium’s recognition of the life sciences sector’s urgent need for AI to tackle rising R&D costs, lengthy development timelines, regulatory complexity, and competitive pressures in bringing new therapies and devices to market.
The investment will drive the creation of tailored AI accelerators and platforms designed specifically for pharma, biotech, and medtech use cases. These include generative AI models for hypothesis generation in drug discovery, predictive analytics to optimize clinical trial design and patient recruitment, real-time monitoring and anomaly detection in manufacturing processes, supply chain forecasting to mitigate disruptions, and AI-driven commercial tools for personalized physician engagement and market access strategies. Agilisium will also expand its life sciences AI Centre of Excellence, hiring additional domain experts, data scientists, and engineers to deliver end-to-end solutions from data strategy to production deployment.
The company has already secured several marquee clients in the sector and plans to partner with 50+ organizations over the next three years. Agilisium’s approach emphasizes regulatory-grade AI ensuring models are explainable, validated on diverse datasets, compliant with FDA, EMA, and CDSCO guidelines, and capable of handling sensitive patient data securely. Early engagements have shown promising results, including 30–50% faster insight generation in R&D, improved trial enrollment efficiency, and significant reductions in manufacturing deviations through predictive quality control.
Agilisium’s leadership highlighted that the life sciences industry is at an inflection point where AI can move from experimental pilots to enterprise-scale impact, but success requires deep domain knowledge, robust data foundations, and a focus on measurable business outcomes. The investment aligns with India’s growing role as a global hub for AI services in life sciences, combining cost-effective talent with high-quality delivery to serve both domestic and international clients.
This move positions Agilisium as a key player in the rapidly evolving AI-for-life-sciences market, where companies are racing to adopt generative and predictive AI to shorten development cycles, lower costs, and bring innovative therapies and devices to patients faster. The initiative is expected to create significant high-skill jobs in India while contributing to global advancements in healthcare innovation.
“AI is no longer optional in life sciences it’s the key to solving the industry’s biggest challenges. Our investment ensures pharma, biotech, and medtech companies can deploy AI that is powerful, compliant, and delivers real results.”
By
HB Team
Related News
